AstraZeneca PLC (ZEG.HM)
| Previous close | 148.50 |
| Open | 147.85 |
| Bid | 149.10 x 0 |
| Ask | 150.55 x 0 |
| Day's range | 148.90 - 149.05 |
| 52-week range | 112.65 - 149.05 |
| Volume | |
| Avg. volume | 15 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names have been often cited as top picks in the pharmaceutical industry, are there hidden gems to look out for or do Eli Lilly and Novo Nordisk remain at the top of the class? Mizuho Healthcare Equity Strategist Jared Holz joins Morning Brief to give insight into the healthcare sector and what investors should keep in mind moving forward. "I think for me, Novo and Lilly are still going to be the top two. You know, as long as they are dominating in this kind of section of the market, it's really tough to not ride these a little bit longer, as far as other players in the GLP one market that might emerge that are of interest or intrigue to investors," Holz says. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino Follow Yahoo Finance's latest coverage on Eli Lilly and Novo Nordisk, weight-loss drugs, and the pharmaceutical industry as a whole: How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs Eli Lilly seeks to expand Zepbound use to treat sleep apnea Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market Why the GLP-1 impact on other industries 'will take years' Eli Lilly unveils new manufacturing plant for GLP-1 pens Novo Nordisk to invest $4.1B in NC facility for GLP-1 drugs Eli Lilly's new Alzheimer's treatment could 'lift' drug market Novo Nordisk stock rises on Wegovy approval in China
Business WireIMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
WILMINGTON, Del., June 25, 2024--Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with IMFINZI in combination wit
Simply Wall St.Admiral Group And Two Other UK Exchange Stocks Estimated As Undervalued For Investment Consideration
The United Kingdom's financial markets are currently poised at a critical juncture, with the FTSE 100's movements closely tied to the upcoming release of May's inflation data and decisions from the Bank of England. Amid these market conditions, identifying undervalued stocks can offer investors potential opportunities for growth in a fluctuating economic environment.
